Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line
NIHR HSRIC
Record ID 32016000387
English
Authors' objectives:
Masitinib is intended to be used as first line therapy for the treatment of primary progressive or relapse-free secondary progressive multiple sclerosis. If licensed, masitinib will offer a novel, oral treatment option for this patient group for whom no licensed therapies are currently available. Masitinib is a highly selective, orally administered tyrosine kinase inhibitor that targets the c-Kit, Lyn and Fyn signalling pathways. Masitinib does not currently have Marketing Authorisation in the EU for any indication.
Multiple sclerosis is a chronic immune-mediated condition of the central nervous system characterised by demyelination and axonal degeneration. Around 107,000 people in the UK currently have multiple sclerosis and there are approximately 6,000 new diagnoses each year. Multiple sclerosis is usually diagnosed between the ages of 20 and 50 years, and is the most common cause of non-traumatic neurological disability in young adults. It causes high levels of disability and impaired quality of life for long periods and is associated with a high rate of unemployment in early adulthood.
The aim of treatment is to relieve symptoms, prevent or delay disability arising from disease progression and promote tissue repair to treat established progression. There are currently no disease-modifying therapies available for primary progressive multiple sclerosis, and options of only limited efficacy for secondary progressive disease. Masitinib is currently in a phase III clinical trial comparing its effect on the Multiple Sclerosis Functional Composite against treatment with placebo.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/masitinib-for-primary-and-relapse-free-secondary-progressive-multiple-sclerosis-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Chronic Disease
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Recurrence
- Thiazoles
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.